Cargando…
Quality Decision-Making Practices in Pharmaceutical Companies and Regulatory Authorities: Current and Proposed Approaches to Its Documentation
BACKGROUND: Pharmaceutical companies and regulatory agencies endeavor to relate their decision making with outcomes to improve future decision making and to ensure that gained knowledge is fed back into a learning system. Nevertheless, such a correlation can only be achieved by documenting the expec...
Autores principales: | Bujar, Magdalena, McAuslane, Neil, Connelly, Patricia, Walker, Stuart R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7704497/ https://www.ncbi.nlm.nih.gov/pubmed/32472442 http://dx.doi.org/10.1007/s43441-020-00167-7 |
Ejemplares similares
-
The Reliability and Relevance of a Quality of Decision Making Instrument, Quality of Decision-Making Orientation Scheme (QoDoS), for Use During the Lifecycle of Medicines
por: Bujar, Magdalena, et al.
Publicado: (2019) -
Evaluating Quality of Decision-Making Processes in Medicines' Development, Regulatory Review, and Health Technology Assessment: A Systematic Review of the Literature
por: Bujar, Magdalena, et al.
Publicado: (2017) -
A Process for Evaluating Quality Decision-Making Practices During the Development, Review and Reimbursement of Medicines
por: Bujar, Magdalena, et al.
Publicado: (2020) -
Use of the Certificate for Pharmaceutical Products (CPP) in 18 Maturing Pharmaceutical Markets: Comparing Agency Guidelines with Company Practice
por: Rodier, Céline, et al.
Publicado: (2020) -
Evaluation of Risk-Based Approaches to the Registration of Medicines: Current Status Among African Regulatory Authorities
por: McAuslane, Neil, et al.
Publicado: (2023)